HomeHealthcare & Life SciencesPharmaceuticals Gamma Aminobutyric Acid Transaminase Deficiency Treatment Market

LATAM Gamma Aminobutyric Acid Transaminase Deficiency Treatment Market Size & Outlook, 2026-2034


LATAM Gamma Aminobutyric Acid Transaminase Deficiency Treatment Market Insights

  • Based on Reed Intelligence findings, the LATAM Gamma Aminobutyric Acid Transaminase Deficiency Treatment Market size reached USD 11.3 Million in 2025 and is expected to grow to USD 24.55 Million by 2034.
  • During 2026–2034, the market is forecasted to advance at a CAGR of 9.03%.
  • Drug Therapy represented the largest share of the Treatment Type market in terms of size in 2025.
  • Among the Treatment Type segments, Supportive Therapy is forecasted to achieve the highest growth and remain the most lucrative through the forecast period.

Other Key Findings


  • The global Gamma Aminobutyric Acid Transaminase Deficiency Treatment Market size saw LATAM holding a share of 6.11% in 2025.
  • United States is forecasted to account for the leading share of the global market by 2034.
  • In LATAM, Brazil is forecasted to be the fastest-expanding market, projected to reach USD 9.92 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 11.3 Million
Market Size In 2034 USD 24.55 Million
Largest segment Drug Therapy
Units Revenue in USD Million
CAGR 9.03% (2026-2034)
Segmnetation Covered
LATAM
  1. Brazil
  2. Mexico
  3. Argentina
  4. Colombia
  5. Chile
Treatment Type
  1. Drug Therapy
  2. Gene Therapy
  3. Supportive Therapy
Route of Administration
  1. Oral
  2. Injectable
Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
End-Use
  1. Hospitals
  2. Specialty Clinics
  3. Homecare Settings
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports